These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 39050857)

  • 41. The T cell in Sjogren's syndrome: force majeure, not spectateur.
    Singh N; Cohen PL
    J Autoimmun; 2012 Sep; 39(3):229-33. PubMed ID: 22709856
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dysregulated Marginal Zone B Cell Compartment in a Mouse Model of Sjögren's Syndrome with Ocular Inflammation.
    Singh N; Chin I; Gabriel P; Blaum E; Masli S
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30314337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome.
    Daridon C; Pers JO; Devauchelle V; Martins-Carvalho C; Hutin P; Pennec YL; Saraux A; Youinou P
    Arthritis Rheum; 2006 Jul; 54(7):2280-8. PubMed ID: 16802367
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pathogenesis and diagnosis of Sjögren's syndrome].
    Witte T
    Z Rheumatol; 2010 Feb; 69(1):50-6. PubMed ID: 20012975
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The complexity of Sjögren's syndrome: novel aspects on pathogenesis.
    Jonsson R; Vogelsang P; Volchenkov R; Espinosa A; Wahren-Herlenius M; Appel S
    Immunol Lett; 2011 Dec; 141(1):1-9. PubMed ID: 21777618
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic inflammation enhances NGF-β/TrkA system expression via EGFR/MEK/ERK pathway activation in Sjögren's syndrome.
    Lisi S; Sisto M; Ribatti D; D'Amore M; De Lucro R; Frassanito MA; Lorusso L; Vacca A; Lofrumento DD
    J Mol Med (Berl); 2014 May; 92(5):523-37. PubMed ID: 24557415
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Deleting Mitochondrial Superoxide Dismutase 2 in Salivary Gland Ductal Epithelial Cells Recapitulates Non-Sjögren's Sicca Syndrome.
    Papinska JA; Durślewicz J; Bagavant H; Deshmukh US
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene expression profiling of epithelium-associated FcRL4
    Verstappen GM; Ice JA; Bootsma H; Pringle S; Haacke EA; de Lange K; van der Vries GB; Hickey P; Vissink A; Spijkervet FKL; Lessard CJ; Kroese FGM
    J Autoimmun; 2020 May; 109():102439. PubMed ID: 32201227
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sjögren's syndrome: immunobiology of exocrine gland dysfunction.
    Fox RI
    Adv Dent Res; 1996 Apr; 10(1):35-40. PubMed ID: 8934921
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of interferon-inducible T cell alpha chemoattractant (CXCL11) in the salivary glands of patients with Sjögren's syndrome.
    Ogawa N; Kawanami T; Shimoyama K; Ping L; Sugai S
    Clin Immunol; 2004 Sep; 112(3):235-8. PubMed ID: 15308116
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aspects of innate immunity in Sjögren's syndrome.
    Low HZ; Witte T
    Arthritis Res Ther; 2011 May; 13(3):218. PubMed ID: 21635716
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epithelial CXCR3-B regulates chemokines bioavailability in normal, but not in Sjogren's syndrome, salivary glands.
    Sfriso P; Oliviero F; Calabrese F; Miorin M; Facco M; Contri A; Cabrelle A; Baesso I; Cozzi F; Andretta M; Cassatella MA; Fiocco U; Todesco S; Konttinen YT; Punzi L; Agostini C
    J Immunol; 2006 Feb; 176(4):2581-9. PubMed ID: 16456020
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Type I interferons in Sjögren's syndrome.
    Yao Y; Liu Z; Jallal B; Shen N; Rönnblom L
    Autoimmun Rev; 2013 Mar; 12(5):558-66. PubMed ID: 23201923
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [A diagnostic and etiologic studies of Sjögren's syndrome--II. On the relationship between Sjögren's syndrome and chronic thyroiditis].
    Tanaka O
    Nihon Jibiinkoka Gakkai Kaiho; 1989 Mar; 92(3):374-82. PubMed ID: 2754526
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Autoantibodies and Sjögren's syndrome: a physiologist's perspective.
    Smith PM; Dawson LJ
    Curr Pharm Biotechnol; 2012 Aug; 13(10):2063-70. PubMed ID: 22208652
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comprehensive review of autoantibodies in primary Sjögren's syndrome: clinical phenotypes and regulatory mechanisms.
    Kyriakidis NC; Kapsogeorgou EK; Tzioufas AG
    J Autoimmun; 2014 Jun; 51():67-74. PubMed ID: 24333103
    [TBL] [Abstract][Full Text] [Related]  

  • 57. B7-H4 deficiency in salivary gland of patients with primary Sjögren's syndrome impairs the regulatory effect on T cells.
    Li X; Yu D; Yu N; Wang X; Li X; Harris DCH; Wang Y
    Int J Rheum Dis; 2017 Apr; 20(4):474-480. PubMed ID: 28217953
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TGF-β Pathway in Salivary Gland Fibrosis.
    Zhang X; Yun JS; Han D; Yook JI; Kim HS; Cho ES
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266300
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lacrimal and salivary gland inflammation in the C3H/Ipr autoimmune strain mouse: a potential mode for Sjögren's syndrome.
    Johnson BC; Morton JI; Trune DR
    Otolaryngol Head Neck Surg; 1992 Apr; 106(4):394-9. PubMed ID: 1565490
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pathogenesis of Sjögren's syndrome-like autoimmune lesions in MRL/lpr mice.
    Hayashi Y; Haneji N; Hamano H
    Pathol Int; 1994 Aug; 44(8):559-68. PubMed ID: 7952145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.